Skip to main content

Paytm

For every payment made, Paytm Payments Bank makes money: Vijay Shekhar Sharma

The founder pointed out that there is a massive opportunity in lending and Paytm is now getting stronger in the deposit taking businesses

 

Paytm is in the stage of business where monetisation is the key and that is the reason the company rolled back its cash back schemes, said Vijay Shekhar Sharma, its founder. The company which literally used cashback as its user acquisition strategy, has found that it has acquired more customers organically than through deals mainly on the basis of better use cases and better service.

“There is money to be made in payments, depends where you are in the value chain,” said Sharma during a fireside chat with Rajan Anandan, managing director, Sequoia Capital as a part of the Global Fintech Fest on July 23.

Sharma said that as a bank, Paytm can make money out of payment transactions. Taking a potshot at his competition which are mostly third party payment apps, Sharma said that as they drive more payments, Paytm gets to make more money. To iterate his case, Sharma mentioned that while payment companies cannot charge merchants for UPI payments, NPCI which manages the payments rails makes money.

As a result of Covid19, Paytm is seeing higher adoption of digital payments among new customers and at the same time repeated use of digital payments among existing consumers.

“If a person was doing ‘X’ number of transactions per week, now he or she is doing atleast 3X,” he added.

While digital payments have grown in the country, Sharma pointed out that there is still a tremendous amount of resistance from consumers. In his systems, an active merchant might be still be doing only five to seven transactions through Paytm per month.

“Tier two, three consumers are still comfortable with cash and that is a reality,” he said.

Further talking about his broader plans in financial services, Sharma said that Paytm is chasing after low cost deposits which can later be used for lending. Citing the case of his acquisition of an insurance company, Sharma said insurance is one vertical which is a source of long term money and that money can be used for lending. But as a payments bank Paytm cannot lend and will partner with non banking lenders to finish the final leg.

“Lending is our ambition, we are trying to bring the deposits in through account deposits, mutual funds, gold and others,” he said.



Sharma added that there is a tremendous opportunity in lending in India, if the country wants to be a USD 5 trillion economy, then over the next three years there is a trillion dollar worth of loans required and banks cannot fulfil that entire need. Any startup which can get a few billion dollars out of the pie to flow through them will stand to gain.

Flipping the tables, Sharma asked for Anandan’s comment on the country’s current funding environment, to which the ex-Google India top executive pointed out that there is no dearth of capital globally, but what COVID-19 has done is made Indian startups more efficient.

“You can see startups restructuring their cost, distributing better over the last four months, overall the quality of the ecosystem will improve,” said Anandan. “Just imagine Paytm which was valued at USD 18 billion in the last round becomes profitable next year, how much value creation would that be.”

Once the ecosystem improves in quality, there is USD 20 trillion deployed at negative interest rates which can find its way into the startup ecosystem, he said.

  

Source: Moneycontrol.com


Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...